| PEMOA32 | The impact of delta and omicron variants in the T-cell response to mRNA vaccination in people living with HIV | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA31 | HIV skews the B cell response to SARS-CoV-2 toward extrafollicular maturation | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA30 | Persistent AP-1-induced immune activation during early SARS-CoV-2 infection revealed by simultaneous single-cell epigenetic and gene expression profiling | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA29 | In vitro release and in vivo pharmacokinetics of antiretroviral drugs from ultra-long-acting polymeric implants: towards better outcomes for HIV prevention and treatment | Poster exhibition | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| PEMOA28 | Pharmacologic intervention to reduce chronic inflammation in people with HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA27 | Clinical and immunometabolic patterns determining efficacy of DC-treatment reinvigorating HIV-1-specific CD8+ T cells in PLWH | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA26 | Developing a novel HIV cure strategy: retargeting potent cytotoxic T cells to kill HIV-infected cells | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PELBF02 | Follow the science - addressing resistance to comprehensive sexuality education: lessons from five African countries | Poster exhibition | Laws, policies and practices impacting access to HIV testing, prevention, treatment, care and support |
| PELBF01 | HIV criminalization laws, public health trust, and uptake of COVID-19 vaccine among people living with HIV in the United States | Poster exhibition | Laws and policies on HIV transmission, exposure, and non-disclosure |
| PELBE02 | Community led monitoring in PEPFAR Vietnam - innovation and lessons learned | Poster exhibition | Effective approaches to linking population and programme data to inform HIV programming |